RMD Resmed Inc

Price (delayed)

$239.99

Market cap

$35.14B

P/E Ratio

44.94

Dividend/share

$1.68

EPS

$5.34

Enterprise value

$35.78B

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea , chronic obstructive pulmonary disease , and other respiratory ...

Highlights
RMD's net income has soared by 64% YoY
The EPS has soared by 63% YoY
Resmed's debt has increased by 16% YoY and by 10% QoQ

Key stats

What are the main financial stats of RMD
Market
Shares outstanding
146.42M
Market cap
$35.14B
Enterprise value
$35.78B
Valuations
Price to earnings (P/E)
44.94
Price to book (P/B)
10.45
Price to sales (P/S)
9.8
EV/EBIT
36.41
EV/EBITDA
30.41
EV/Sales
10
Earnings
Revenue
$3.58B
EBIT
$982.8M
EBITDA
$1.18B
Free cash flow
$216.31M
Per share
EPS
$5.34
Free cash flow per share
$1.48
Book value per share
$22.97
Revenue per share
$24.5
TBVPS
$19.26
Balance sheet
Total assets
$5.1B
Total liabilities
$1.74B
Debt
$917.55M
Equity
$3.36B
Working capital
$1.24B
Liquidity
Debt to equity
0.27
Current ratio
2.8
Quick ratio
1.23
Net debt/EBITDA
0.55
Margins
EBITDA margin
32.9%
Gross margin
56.6%
Net margin
21.8%
Operating margin
28%
Efficiency
Return on assets
16%
Return on equity
24.3%
Return on invested capital
38.4%
Return on capital employed
22.3%
Return on sales
27.5%
Dividend
Dividend yield
0.7%
DPS
$1.68
Payout ratio
31.5%

RMD stock price

How has the Resmed stock price performed over time
Intraday
-0.36%
1 week
-0.75%
1 month
11.22%
1 year
-12.79%
YTD
-7.87%
QTD
14.48%

Financial performance

How have Resmed's revenue and profit performed over time
Revenue
$3.58B
Gross profit
$2.02B
Operating income
$1B
Net income
$779.44M
Gross margin
56.6%
Net margin
21.8%
RMD's net income has soared by 64% YoY
Resmed's net margin has increased by 47% YoY
The company's revenue rose by 12% YoY
RMD's operating income is up by 11% YoY

Growth

What is Resmed's growth rate over time

Valuation

What is Resmed stock price valuation
P/E
44.94
P/B
10.45
P/S
9.8
EV/EBIT
36.41
EV/EBITDA
30.41
EV/Sales
10
The EPS has soared by 63% YoY
The price to earnings (P/E) is 23% lower than the last 4 quarters average of 58.4 and 6% lower than the 5-year quarterly average of 47.9
RMD's equity is up by 16% year-on-year and by 2.5% since the previous quarter
RMD's P/B is 12% above its 5-year quarterly average of 9.3 but 7% below its last 4 quarters average of 11.2
The P/S is 23% higher than the 5-year quarterly average of 8.0 but 4.9% lower than the last 4 quarters average of 10.3
The company's revenue rose by 12% YoY

Efficiency

How efficient is Resmed business performance
The ROA has soared by 55% YoY
Resmed's ROE has increased by 43% YoY but it has decreased by 4% from the previous quarter
The company's return on invested capital fell by 7% QoQ and by 6% YoY
The ROS has decreased by 3.2% YoY

Dividends

What is RMD's dividend history
DPS
$1.68
Dividend yield
0.7%
Payout ratio
31.5%
Recent dividends

Financial health

How did Resmed financials performed over time
The company's total assets is 194% higher than its total liabilities
The current ratio has soared by 62% YoY and by 10% from the previous quarter
Resmed's quick ratio has increased by 23% YoY and by 16% from the previous quarter
Resmed's debt is 73% lower than its equity
Resmed's debt has increased by 16% YoY and by 10% QoQ
RMD's equity is up by 16% year-on-year and by 2.5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.